Licensing status

Publication and contact information


Parkinson's disease (PD)

Opiate receptor-like 1 (OPRL1)

Rat and primate studies suggest OPRL1 agonists could help treat dyskinesias induced by the PD drug l-dopa. In a rat model of l-dopa-induced dyskinesia (LID), exogenous nociceptin or an agonist targeting the nociceptin receptor OPRL1 decreased LID and increased motor functions compared with saline control. In a nonhuman primate model for PD with LID, the OPRL1 agonist decreased dyskinesia compared with saline without decreasing the therapeutic effect of l-dopa. Next steps include lead identification and optimization of OPRL1 agonists.

SciBX 5(47); doi:10.1038/scibx.2012.1241
Published online Dec. 6, 2012

Patents filed internationally and in Italy; use of OPRL1 agonists for LID is available for licensing

Marti, M. et al. J. Neurosci.; published online Nov. 14, 2012;
Contact: Michele Morari, University of Ferrara, Ferrara, Italy